Moderna Inc. on Sept. 1 asked the U.S. Food and Drug Administration to allow the use of a third booster dose of the company’s Covid-19 vaccine.
BeiGene Ltd.’s Brukinsa (zanubrutinib) received approval from the U.S. Food and Drug Administration for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
The U.S. Food and Drug Administration greenlit Janssen’s long-acting, twice-per-year schizophrenia drug Invega Hafyera (paliperidone palmitate six-month).
A study published in the Journal of the American Medical Association by Belgium researchers comparing the Moderna and Pfizer-BioNTech Covid-19 vaccines found that the Moderna jabs generated twice the antibodies as the Pfizer-BioNTech vaccine.
Astellas Pharma paused the screening and dosing of an investigational gene therapy for patients with X-linked Myotubular My-opathy (XLMTM) following a serious adverse event report in a trial participant.
Pfizer Inc. started dosing in a mid-to-late-stage trial of the company’s oral antiviral therapy for Covid-19 in non-hospitalized, symptomatic adult patients.
Merck & Co. and partner Ridgeback Biotherapeutics said on Wednesday they had begun enrolling patients in a late-stage trial of their experimental drug molnupiravir for the prevention of Covid-19 infection.
In a survey released by oncology data leader COTA, half of the respondents pointed to “Operation Warp Speed” for the Covid-19 pandemic as the seed of their belief that cancer treatments can and should be moving forward faster.
AC Immune and Genentech announced that their Phase II Lauriet trial of semorinemab in mild-to-moderate Alzheimer’s disease hit one of the study’s co-primary endpoints.
A new study on Covid-19 behavior has found that patients affected by the virus might have died due to a buildup of coronavirus directly in the lungs and not because of a secondary infection.
